GE HealthCare Technologies Inc. (GEHC)
Fair ValueFundamental
54
मूल्य
$65.37
मार्केट कैप
$30.20B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
GE HealthCare makes the diagnostic imaging equipment hospitals use to see inside the body — MRI, CT, X-ray, ultrasound and PET scanners — plus the contrast agents and radioactive tracers that make those scans clearer and the monitors and ventilators used to track patients at the bedside. Spun off from General Electric in 2023, it sells mainly to hospitals and health systems worldwide, competing in a market shared by a small number of large, similarly capable equipment makers.
यह पैसा कैसे कमाती है
Revenue mixes large, lumpy equipment sales — an MRI or CT scanner can cost hospitals millions of dollars — with recurring, higher-margin revenue from service contracts, software and the imaging agents and tracers that must be repurchased for every scan. Equipment sales depend on hospital capital budgets and can be deferred, while service and consumable revenue is stickier once a machine is installed. AI-enabled software features are an increasing share of what GE HealthCare sells alongside the hardware.
सेगमेंट के अनुसार राजस्व
MRI, CT, X-ray, ultrasound and PET imaging equipment plus the advanced visualization software used to interpret the images.
Patient monitors, ventilators, anesthesia delivery and other equipment used to track and support patients at the bedside.
Contrast agents and radioactive tracers injected into patients to make imaging scans clearer and diagnoses more precise.
Financial services supporting equipment leasing and purchases, a small residual outside the three main product lines.
प्रतिस्पर्धी बढ़त (Moat)
स्विचिंग कॉस्ट · संकीर्णHospitals that buy a GE HealthCare scanner also commit to years of service contracts, staff training and integration with existing IT systems, making a switch to a rival brand costly and disruptive. That lock-in supports recurring service and consumables revenue, but Siemens Healthineers and Philips offer comparably capable equipment, so hospitals do switch brands at each new purchase cycle.
मांग को क्या चलाता है
मध्यम रूप से चक्रीयHealthcare spending overall is fairly defensive, but big-ticket imaging equipment purchases are capital decisions hospitals can postpone when budgets tighten or interest rates rise, unlike the recurring consumables and service revenue tied to machines already installed. Aging populations and rising diagnostic scan volumes support long-term demand, while hospital reimbursement and capital-spending cycles create shorter-term swings.
प्रमुख जोखिम
- Hospital capital spending cycles — Large equipment purchases can be postponed when hospital budgets tighten or financing costs rise, creating lumpy order flow that does not track the steadier growth of the underlying diagnostics market.
- Spin-off leverage — GE HealthCare took on new debt as part of its 2023 separation from General Electric; that leverage leaves less room to absorb a downturn or fund acquisitions than a business with a cleaner balance sheet.
- Competition from Siemens Healthineers and Philips — Both rivals sell comparably capable imaging and patient-monitoring equipment, and hospitals routinely evaluate all major vendors at each replacement cycle, limiting GE HealthCare's pricing power.
- Regulatory and product approval risk — Medical devices, imaging agents and radiopharmaceuticals require regulatory clearance in every market sold; delays, recalls or stricter rules can push back launches or force costly remediation.
ग्राहक Concentration
GE HealthCare sells to thousands of hospitals and health systems across more than 100 countries, so no single customer accounts for a material share of revenue.
खरीदने के पक्ष में तर्क
Buyers argue that GE HealthCare's installed base of imaging equipment across thousands of hospitals generates durable, high-margin recurring service and consumables revenue, and that aging populations and expanding diagnostic and AI-enabled software use support years of underlying growth.
बेचने के पक्ष में तर्क
Sellers fear that big-ticket equipment sales are exposed to hospital capital-spending cuts, that debt taken on at the 2023 spin-off limits financial flexibility, and that Siemens Healthineers and Philips can match GE HealthCare's technology closely enough to keep pricing power in check.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
GE HealthCare's 10-K names it a primary global competitor: the two sell the same CT, MRI, X-ray, molecular imaging and ultrasound systems, plus service contracts, to the same hospitals and imaging centres worldwide.
Named in the 10-K as a primary competitor: Philips bids against GE HealthCare on imaging systems, ultrasound and above all on hospital patient monitoring, the heart of GE's Patient Care Solutions segment.
Through its Canon Medical Systems subsidiary, named in GE HealthCare's 10-K, it sells competing CT, MRI, X-ray and ultrasound systems to the same hospital buyers, pushing hard on mid-range price-performance.
Named in the 10-K, Mindray competes directly for the same patient-monitoring, anaesthesia and ultrasound budgets, and has become the volume alternative in China and other emerging markets.
Also named in the 10-K, it sells high-specification CT, MRI and PET systems at lower prices, taking imaging tenders from GE HealthCare first in China and increasingly abroad.
In the Pharmaceutical Diagnostics segment, the 10-K names Bayer as a direct rival: both supply the contrast media injected during CT and MRI scans, sold to the same hospitals and radiology chains.
बैलेंस शीट और तरलता
राजस्व
$20.98B
पिछले 12 महीने (31/3/2026 तक)
शुद्ध आय
$1.91B
पिछले 12 महीने (31/3/2026 तक)
Free Cash Flow
$1.50B
कुल इक्विटी
$10.38B
कुल देनदारियाँ
$26.31B
Current Ratio
1.22
Interest Coverage
-
Debt/EBITDA
2.94
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$63.46
वर्तमान मूल्य
$65.37
Margin of Safety
-3.0%
Fair Value सीमा
$47.93 - $78.98
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
15.68
ROE
20.1%
P/B Ratio
2.79
P/FCF
19.58
Gross Margin
39.1%
ROIC
7.3%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
7.3%
WACC
6.7%
ROIC − WACC
+0.6 pp
ROIC लगभग पूंजी की लागत के बराबर है — कंपनी मुश्किल से अपनी पूंजी लागत की भरपाई कर पा रही है।
Fundamental विश्लेषण मानदंड
पास (15)
- ROIC 7.3%
- Gross Margin 39.1%
- P/FCF 19.58
- P/B Ratio 2.79
- Debt/Equity ratio
- Operating Margin 12.6%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 18.9%
- Analyst Consensus 68% Buy
- Earnings Quality (OCF/NI) 1.06
- Share Dilution -0.3%
- Piotroski F-Score 5/9
फेल (10)
- EPS shows upward trend
- EPS CAGR -2.08%
- Price CAGR 3.15%
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Revenue Growth 5Y 3.7%
- Earnings Surprise avg 0.1%
- Net Margin Trend 9.1% vs 11.0%
अनुपलब्ध (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Peter J. Arduini | President, CEO & Director | 60 |
| Dr. Taha Kass-Hout M.D., M.S. | Chief Science & Technology Officer | 53 |
| Mr. Frank R. Jimenez Esq. | General Counsel & Corporate Secretary | 60 |
| Ms. Jeannette Bankes | President & CEO of Patient Care Solutions | 54 |
Audit जोखिम
1
बोर्ड जोखिम
5
मुआवजा जोखिम
5
शेयरधारक अधिकार जोखिम
5
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-04
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-07-29
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-09-22
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for GEHC, sourced from Markets Gazette.
- 28d agoNEGATIVEThese stocks in the red-hot healthcare sector have gotten too crowded to own
Analysts are recommending an options strategy to bet against GE HealthCare, citing that the stock has become too crowded with bullish positions. This suggests a potential for a sharp reversal if sentiment shifts or if the company fails to meet elevated expectations. The crowded nature of the trade implies that many investors have already piled into the healthcare stock, increasing the risk of a significant sell-off. For investors, this signals a potential downside risk and a need for caution in the short term.
via Markets Gazette